Genmab — September 2018
-
Hva satan!? Klinisk effekt på en GEN duobody!
-
-
Janssen må nu hurtigst muligt få aktiveret militærapparatet, så JNJ......372 kommer lynhurtigt gennem faserne og ud til patienterne:-)
-
Legolas man skal huske på to ting vedrørende dette - for det første var dette en af de første aftaler på DuoBody, som på pågældende tidspunkt var en teknologi uden ret meget vallidering, så faktisk ligger alle andre programmer i denne aftale med en royalty under 10%. For det andet er det jo aftaler der alene beror sig på tech transfer, så Genmab yder som sådan ikke det store arbejde.
-
-
404: This page could not be found.BerGenBio - Developing first-in-class AXL inhibitors for aggressive disease
BerGenBio: Developing first-in-class AXL inhibitors for aggressive diseases, including advanced, treatment resistant cancers
(www.bergenbio.com)
antibody platform
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind